Atlas Trials

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Clinical trial NCT06687369 · RECRUITING

Trial details

NCT number
NCT06687369
Sponsor
mAbxience Research S.L.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non Squamous Non Small Cell Lung Cancer
Start date
2024-12-30
Primary completion
2026-06-01
Enrollment
726

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.